Paul Feuerstadt, MD, FACG, AGAF, discusses the key findings from the phase 3 ECOSPOR clinical trial for fecal microbiota spores, live-brpk oral capsules (VAS).
Video content above is prompted by the following:
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.